Walk In, Roll Out: The Conundrum of Cardio Exercise with MS
In pursuit of an answer for breathing difficulty The MRI of my cervical and thoracic spine showed no active lesions last week. That was good news. Other…
In pursuit of an answer for breathing difficulty The MRI of my cervical and thoracic spine showed no active lesions last week. That was good news. Other…
Telemedicine, which allows healthcare professionals to evaluate, diagnose and treat patients at a distance with telecommunications technology, may soon benefit people with multiple sclerosis (MS). Elizabeth Morrison-Banks, MD, a health sciences clinical professor at theĀ University of California at RiversideĀ School of Medicine,Ā is planning a pilot one-year study of a home-based…
The idea of repairing damaged axons ā a key component of advancing disability in multiple sclerosis (MS) ā just got closer to reality, with the discoveryĀ that a compound found in fungi triggered axon regeneration, making damaged axons grow ālike weeds.ā Scientists have long struggled to find compounds that stimulate the…
A new test can show how exercise is benefiting people with multiple sclerosis (MS) and other neurological conditions. The evaluation of muscle health inĀ individuals with MS, spinal cord injuries and other severe nerve damage conditions is usually done with magnetic resonance imaging (MRI) and other expensive equipment. Researchers in the…
Kinesiology professor Richard van Emmerik and his colleagues at the University of Massachusetts AmherstĀ recently received a two-year $833,000 grant from the U.S.Ā Department of Defense to create an improved diagnostic test for multiple sclerosis (MS). The scientists expects their research toĀ help an estimated 2.3 million people worldwideĀ who live with…
Molecular diagnostics startupĀ IQuity is introducing a pioneering blood test that speeds upĀ multiple sclerosis (MS) diagnosis to just seven days. Previously, this process could take up to months or years. IQuity, based in Nashville, Tennessee, began working on its new IsolateMS blood test in January 2016, after receiving $2…
Australians living with multiple sclerosis (MS) don’t haveĀ adequate access to dental care, a new study reports. The study, āHow do Australians living with MS experience oral health and accessing dental care? A focus group study,ā appearedĀ in the journalĀ Community Dentistry and Oral Epidemiology. MS is an autoimmune…
This year’s annualĀ Walk MS event will bring cumulative fundraising for multiple sclerosis (MS) and the National Multiple Sclerosis SocietyĀ (NMSS) since 1988 to more thanĀ $1 billion, say organizers. āWalk MS is a joyous gathering with a wonderful ‘we’re in this together’ feeling,ā NMSS President and CEO Cyndi ZagieboyloĀ said…
As Republicans in Congress prepare to repeal and replaceĀ the Affordable Care Act (ACA), the National Multiple Sclerosis SocietyĀ andĀ 10 other nonpartisan patient groups are urging lawmakers in Washington to keep health insurance affordable, accessible, adequate and understandable for all Americans. The 11 organizations will evaluate all proposed changes to the…
Riding and other activities with horses can help adults and children with the balance, gait, and psychomotor disorders that are hallmarks of multiple sclerosis, according to review of 16 studies. The review, āTherapeutic Effects of Horseback Riding Interventions: A Systematic Review and Meta-analysis,ā was published in theĀ …
People with secondary progressive multiple sclerosis (SPMS)Ā are more likely to feel exhausted and haveĀ limited leg function than those without progressive MS as they age, a preliminary study suggests. The findings will be presented atĀ the American Academy of Neurology (AAN) 69th Annual Meeting, set for April 22-28 in Boston.
It is no coincidence that multiple sclerosis (MS) patients are prone to airway infections, according to research showing that MS disease processes allow suppressive immune cells to travel to the lungs and block inflammatory responses against invading viruses. The study may offer guidance on how vaccines should be used to…
Australia’sĀ Innate Immunotherapeutics confirmed that its Phase 2b clinical trial evaluating the drug MIS416 in patients with secondary progressive multiple sclerosis (SPMS) will wrap up by April 30, as scheduled, and data is expected to be release in the fall. MIS416 is a biologically derived new immune modulator that can…
A number of multiple sclerosis organizations have joined BiogenĀ in the second year of the #MySupportHero initiative. The social media campaign is a way forĀ people with multiple sclerosis (MS)Ā Ā toĀ thank those who give them the care, Ā encouragement, attention, and strength they need. The initiative runs through the end ofĀ March, which…
On a Monday in July, the Multiple Sclerosis Association of America (MSAA) gave Kathy, who loves to hike in the woods, a cooling vest that reduces heat stress ā a common issue for people with multiple sclerosis (MS).Ā On a Wednesday in October, the nonprofitĀ funded an MRI for Sarah,…
Medicare spent moreĀ $650 million in 2013 and 2014 on one singleĀ medication ā H.P. Acthar Gel āā that was prescribed by fewer than 1 percentĀ of clinicians to treat multiple sclerosis (MS), with questionable results. That’s the conclusion of new research byĀ Oregon Health and Science University (OSHU), which presented its…
March 28, at the latest, may be a historic date for the multiple sclerosis (MS) community ā patients, families, caregivers, researchers, and physicians alike. The U.S. Food and Drug Administration (FDA) will have its say about the marketing approval forĀ Ocrevus (ocrelizumab). The drugĀ willĀ be the first to offerĀ benefit to…
BelowĀ is a transcript of theĀ Multiple Sclerosis News TodayĀ interview with Dr. Peter Chin ā principal medical director at Genentech ā about the importance of the pending U.S. Food and Drug Administration (FDA) approval of a Biologics Licensing Application (BLA) for Ocrevus (ocrelizumab). An an indepth article on this interview,Ā lookingĀ Ocrevus…
Ten years after completingĀ treatment with Novantrone (mitoxantrone), a chemotherapy drug, multiple sclerosis (MS) patients showed evidence of markedly lowerĀ annualized relapse rates, but the therapy’s effects began to wane after five years, a studyĀ presented atĀ ACTRIMS 2017 ForumĀ reported. The study also assessed howĀ Novantrone affects disease progression in primary and secondary progressive…
The absence of epigenetic factors in myelin-producing oligodendrocyte cells make sure that myelin production is switched off in the adult brain. Targeting these factors may be a way of triggering myelin regeneration in multiple sclerosis (MS), and a step towardĀ personalized medicine for this disease, Dr. Patrizia Casaccia said in aĀ talk…
Sex hormones, and genes in the two sex chromosomes, impact the risk of multiple sclerosis (MS) in men and women differently, and lead to differences in the course of the disease between the sexes, according to two studies. Two speakers at the ACTRIMS 2017 ForumĀ highlighted the role of sex…
A detailed analysis ofĀ relapsing and primary progressive multiple sclerosis (MS) patients in the three Phase 3 trials of Ocrevus (ocrelizumab) showed that the treatment did not significantly increase their risk of infections ā serious or otherwise. Certain infections, including common colds and influenza, were numerically more common among Ocrevus-treated patients,…
Short-chain dietary fatty acids, such as propionate, drive the production of regulatory immune T-cells in patients with multiple sclerosis (MS), while long-chain acids promote T-cells that are involved in inflammatory processes. Since the beneficial fatty acids are safe and can be obtained as over-the-counter dietary supplements, researchers suggest they could…
Spending more time in the sunshineĀ could make people with multiple sclerosis (MS) feel more energetic, though dietary vitamin D intake’s effect is mixed, depending on what type of MS a particular patient has. That’s the conclusion of a study āĀ “Dietary intakes of vitamin D, sunshine exposure, EDSS and fatigue…
Genentechās Ocrevus (ocrelizumab) increased the proportion of patients with no evidence of progression (NEP) in the recently concluded ORATORIO Phase 3 clinical trial in patients with primary progressive multiple sclerosis (PPMS). The evaluation of NEPĀ ā a combined measure of three disability assessments ā was a secondary exploratory endpoint of…
Disease processes in multiple sclerosis (MS) likely contribute to the increased sensitivity to airway infections seen in MS patients,Ā a series of experiments in mice demonstrated. The study, presented at theĀ ACTRIMS 2017 Forum, showed that suppressive immune cells travel to the lungs and prevent an essential inflammatory reaction to viral…
The Brazilian government has authorizedĀ HempMeds Brasil, a unit of California-basedĀ Medical Marijuana, to import the parent company’sĀ hemp cannabidiol (CBD) oil flagship product ā known as Real Scientific Hemp Oil (RSHO) āĀ for the management of multiple sclerosis (MS) symptoms. This is the first time Brazil’s National Health Surveillance Agency…
Treatment with Apitopeās lead agent, ATX-MS-1467, decreased brain lesions in patients with relapsing multiple sclerosis (MS) in a now-completed Phase 2aĀ clinical trial. ATX-MS-1467 is a potential disease-modifying agent with anĀ immune-tolerating action. It consists of four short peptides derived from the myelin basic protein, and is designed to reduce…
FatigueĀ isĀ the bane of my existence. Clutter qualifies as my lifestyle. If I can’t see something it may as well beĀ lost. I spend about 50% of my day trying to find things I have put “someplace safe.” The other half I spend looking for something IĀ just had…
Results from aĀ Phase 2 proof-of-concept studyĀ ofĀ ADS-5102Ā (amantadineĀ HCl), showing that multiple sclerosis patients givenĀ the extended-release oral treatment improved their walking speed, will be presentedĀ at ACTRIMS 2017Ā this week. Findings in theĀ poster, āA Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,ā…
Get regular updates to your inbox.